Savolitinib

CAT: 0804-HY-15959-01Size: 5 mgDry Ice: NoHazardous: No

1 / 1

CAT#:0804-HY-15959-01Size:5 mg

Selected

24/48H Stock Items & 2 to 6 Weeks non Stock Items.

Quick Request Actions

Description

Savolitinib (AZD-6094) is a potent, highly selective, and orally bioavailable c-Met inhibitor with IC50 s of 5 nM and 3 nM for c-Met and p-Met, respectively. Savolitinib (AZD-6094) selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. Antineoplastic activity[1][2].

CAS Number

1313725-88-0

Product Name Alternative

Volitinib; HMPL-504; AZD-6094

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

C-Met/HGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Savolitinib.html

Purity

99.99

Solubility

DMSO : ≥ 20.83 mg/mL

Smiles

CN1N=CC(C2=CN=C3C(N([C@H](C4=CN5C(C=C4)=NC=C5)C)N=N3)=N2)=C1

Molecular Formula

C17H15N9

Molecular Weight

345.36

Precautions

H302, H315, H319, H335

References & Citations

[1]Jia H, et al. Discovery of (S) -1- (1- (Imidazo[1,2-a]pyridin-6-yl) ethyl) -6- (1-methyl-1H-pyrazol-4-yl) -1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer. J Med Chem. 2014 Sep 25;57 (18) :7577-89.|[2]Gavine PR, et al. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models. Mol Oncol. 2015 Jan;9 (1) :323-33.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Chemical Information

Savolitinib

Savolitinib is a member of the class of triazolopyrazines that is 1H-[1,2,3]triazolo[4,5-b]pyrazine substituted by (1S)-1-(imidazo[1,2-a]pyridin-6-yl)ethyl and 1-methyl-1H-pyrazol-4-yl groups at positions 1 and 6, respectively. It is a highly selective MET tyrosine kinase inhibitor that is approved in China for advanced NSCLC with MET exon 14 skipping mutations. It has a role as an antineoplastic agent and a c-Met tyrosine kinase inhibitor. It is a member of pyrazoles, an imidazopyridine and a triazolopyrazine.

CAS Number	1313725-88-0
PubChem CID	68289010
IUPAC Name	3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine
Molecular Formula	C17H15N9
Molecular Weight	345.4
XLogP	1.5
Topological Polar Surface Area	91.6
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	3
Heavy Atom Count	26
Formal Charge	0
Complexity	505

SMILES

C[C@@H](C1=CN2C=CN=C2C=C1)N3C4=NC(=CN=C4N=N3)C5=CN(N=C5)C

InChI

InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1

InChIKey

XYDNMOZJKOGZLS-NSHDSACASA-N

Chemical Structure

2D Structure

CAS: 1313725-88-0

CID: 68289010

Formula: C17H15N9

MW: 345.4

Interactive 3D Structure

Loading 3D structure...

View on PubChem Raw 3D data

Computed Properties

Property	Value
Molecular Weight	345.4
XLogP3	1.5
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	3
Exact Mass	345.14504152
Monoisotopic Mass	345.14504152
Topological Polar Surface Area	91.6 Å²
Heavy Atom Count	26
Formal Charge	0
Complexity	505
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently-Bonded Unit Count	1
Compound Is Canonicalized	Yes

Alternative Products

Catalog	Name
BA8873-25	Savolitinib
C12862-25mg	Savolitinib (AZD6094)

Savolitinib

Chemical Information

Alternative Products

Popular Products